Compare Stocks: CRBP, OCS, SPRY, and CRMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$8.97 -0.9%	$8.62	$7.12 ▼ $20.56	$166.20M	2.55	266,345 shs	351,704 shs
CRMD CorMedix	$7.53 +0.5%	$8.31	$6.13 ▼ $14.96	$590.74M	1.48	886,873 shs	637,871 shs
OCS Oculis	$11.31 +0.9%	$13.78	$10.52 ▼ $34.47	$655.80M	0.44	328,292 shs	204,845 shs
SPRY ARS Pharmaceuticals	$5.13 -8.9%	$8.18	$5.11 ▼ $18.00	$509.42M	0.95	2.19 million shs	2.08 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	0.00%	-2.18%	-3.03%	-12.91%	-3.13%
CRMD CorMedix	0.00%	-4.32%	-13.94%	-3.34%	-34.75%
OCS Oculis	0.00%	+1.62%	-19.90%	-58.84%	-36.21%
SPRY ARS Pharmaceuticals	0.00%	-13.64%	-40.07%	-40.07%	-71.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$8.97 -0.9%	$8.62	$7.12 ▼ $20.56	$166.20M	2.55	266,345 shs	351,704 shs
CRMD CorMedix	$7.53 +0.5%	$8.31	$6.13 ▼ $14.96	$590.74M	1.48	886,873 shs	637,871 shs
OCS Oculis	$11.31 +0.9%	$13.78	$10.52 ▼ $34.47	$655.80M	0.44	328,292 shs	204,845 shs
SPRY ARS Pharmaceuticals	$5.13 -8.9%	$8.18	$5.11 ▼ $18.00	$509.42M	0.95	2.19 million shs	2.08 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	0.00%	-2.18%	-3.03%	-12.91%	-3.13%
CRMD CorMedix	0.00%	-4.32%	-13.94%	-3.34%	-34.75%
OCS Oculis	0.00%	+1.62%	-19.90%	-58.84%	-36.21%
SPRY ARS Pharmaceuticals	0.00%	-13.64%	-40.07%	-40.07%	-71.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$42.25	371.01% Upside
CRMD CorMedix	2.75	Moderate Buy	$14.86	97.31% Upside
OCS Oculis	2.80	Moderate Buy	$38.33	238.93% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$28.20	449.71% Upside

Current Analyst Ratings Breakdown

Latest CRBP, OCS, SPRY, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
6/25/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$25.00 ➝ $24.00
6/23/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$44.00 ➝ $34.00
6/17/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$54.00 ➝ $52.00
6/11/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/3/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$42.00 ➝ $23.00
6/1/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$49.00 ➝ $38.00
6/1/2026	OCS Oculis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $40.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
CRMD CorMedix	$311.71M	1.90	$2.05 per share	3.68	$5.14 per share	1.46
OCS Oculis	$1.45M	452.24	N/A	N/A	$4.08 per share	2.77
SPRY ARS Pharmaceuticals	$84.28M	6.04	N/A	N/A	$1.16 per share	4.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$78.54M	-$5.82	N/A	N/A	N/A	N/A	-70.89%	-61.78%	8/11/2026 (Estimated)
CRMD CorMedix	$163.05M	$2.13	3.54	753.00	N/A	45.25%	45.57%	24.76%	8/13/2026 (Estimated)
OCS Oculis	-$119.44M	-$2.13	N/A	N/A	N/A	-8,460.67%	-56.78%	-45.62%	8/6/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.01	N/A	N/A	N/A	-200.00%	-153.61%	-60.85%	8/12/2026 (Estimated)

Latest CRBP, OCS, SPRY, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.26	N/A	N/A	N/A	$96.04 million	N/A
8/12/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4766	N/A	N/A	N/A	$31.33 million	N/A
8/11/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.30	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	OCS Oculis	-$0.48	N/A	N/A	N/A	$0.23 million	N/A
5/15/2026	Q1 2026	SPRY ARS Pharmaceuticals	-$0.53	-$0.61	-$0.08	-$0.61	$22.20 million	$22.68 million
5/14/2026	Q1 2026	CRMD CorMedix	$0.35	$0.43	+$0.08	$0.43	$104.96 million	$127.43 million
5/12/2026	Q1 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.23	+$0.03	-$1.23	N/A	N/A
5/8/2026	Q1 2026	OCS Oculis	-$0.49	-$0.63	-$0.14	-$0.61	$0.25 million	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	7.92	7.92
CRMD CorMedix	0.33	2.97	2.74
OCS Oculis	0.01	5.18	5.18
SPRY ARS Pharmaceuticals	2.79	4.94	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CRMD CorMedix	34.18%
OCS Oculis	22.30%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	3.50%
CRMD CorMedix	3.50%
OCS Oculis	N/A
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	18.53 million	17.88 million	Optionable
CRMD CorMedix	30	78.45 million	75.71 million	Optionable
OCS Oculis	2	57.98 million	N/A	Not Optionable
SPRY ARS Pharmaceuticals	90	99.30 million	65.74 million	Optionable

CRBP, OCS, SPRY, and CRMD Headlines

Recent News About These Companies

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 8.2% - Should You Sell?

July 31 at 3:19 PM | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sees Strong Trading Volume - Time to Buy?

July 29, 2026 | marketbeat.com

ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

ARS Pharmaceuticals, Inc. $SPRY Shares Acquired by Rubric Capital Management LP

July 28, 2026 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Time to Sell?

July 27, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 23, 2026 | prnewswire.com

Levin Capital Strategies L.P. Has $4.44 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY

July 23, 2026 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Moderate Buy" by Analysts

July 23, 2026 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 21, 2026 | globenewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 18, 2026 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.2% - Here's Why

July 17, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 16, 2026 | prnewswire.com

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

July 15, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 14, 2026 | globenewswire.com

General American Investors Co. Inc. Buys 167,195 Shares of ARS Pharmaceuticals, Inc. $SPRY

July 12, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN) and ARS Pharmaceuticals (SPRY)

July 11, 2026 | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 9, 2026 | prnewswire.com

Can ARS Pharma's New CEO Unlock Neffy's Potential?

July 9, 2026 | benzinga.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

July 7, 2026 | globenewswire.com

ARS Pharmaceuticals appoints Donn Casale as CEO

July 7, 2026 | tipranks.com

ARS Pharmaceuticals Announces CEO Succession

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, OCS, SPRY, and CRMD Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$8.97 -0.08 (-0.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.96 -0.01 (-0.11%)

As of 07/31/2026 07:34 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CorMedix NASDAQ:CRMD

$7.53 +0.04 (+0.53%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.52 -0.01 (-0.13%)

As of 07/31/2026 05:08 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Oculis NASDAQ:OCS

$11.31 +0.10 (+0.89%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$11.24 -0.07 (-0.57%)

As of 07/31/2026 07:34 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

ARS Pharmaceuticals NASDAQ:SPRY

$5.13 -0.50 (-8.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.25 +0.12 (+2.36%)

As of 07/31/2026 07:56 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, OCS, SPRY, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, OCS, SPRY, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, OCS, SPRY, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, OCS, SPRY, and CRMD Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

CorMedix NASDAQ:CRMD

Oculis NASDAQ:OCS

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, OCS, SPRY, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, OCS, SPRY, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, OCS, SPRY, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, OCS, SPRY, and CRMD Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

CorMedix NASDAQ:CRMD

Oculis NASDAQ:OCS

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools